Dr. Tai Ho Chung, Ph. D. M.D.
Partner, Scientific Advisor and Inventor of Tubercin
Career Objective:
To bring to the world the successful implementation of Tubercin to effectively combat Cancer. As a partner in ArTec, Inc., his role is to insure the scientific aspects of accomplishing our ArTec, Inc.'s missions are met. Specifically, Dr. Chung will play a key role in the successful application and approvals for both United States Food and Drug Administration (FDA) and Korean FDA. Dr. Chung is an integral part of ArTec, Inc., in fulfilling its scientific medical goals and objectives.
Professional Experiences:
Dr. Chung is currently the Director of the World Health Organization Collaborating Centre for Immunological Research and the Prevention and Control of Viral Hepatitis and its Related Disease, in Taegu, Korea. The centre is located at the Kyungpook National University (KNU) School of Medicine, in Taegu, South Korea. He has been the director for the past five years. In addition, he has been the former Dean of the School of Medicine, KNU, Taegu Korea. He is the inventor of Tubercin and also Hepaguard (recently approved by Korean FDA) which is a medical remedy to combat Hepatitis A, B, C, D, and E. Dr. Chung is a distinguished scientist and well versed in medical research of viral diseases such as Cancer and Hepatitis.
Education and Achievements:
Dr. Chung received his Doctor of Medicine from Kyungpook National University in Taegu, Korea in 1958. He received his M.S. degree in 1962 and received his Ph. D. in 1968 from Kyungpook National University in Taegu, Korea. He is a member of the Board of Trustees of the Korean Cancer Society, Korean Immunology Society and a member of the prestigious New York Science Academy. Dr. Chung has been a visiting professor in the United States, Denmark, Brussels, etc. He has authored more than 121 publications.
artec-inc.net |
